lp-a.org

Inflammation

Combined elevation of Lp(a) and fibrinogen amplifies 20-year ASCVD risk in the ATTICA study (Eur J Prev Cardiol 2026)

Original title: The interplay of fibrinogen and lipoprotein(a) with 20-year atherosclerotic cardiovascular disease risk: a path analysis within the ATTICA study (2002-2022)

Eur J Prev Cardiol · · 6

Giannakopoulou SP, Chrysohoou C, Antonopoulou S, Barkas F, Liberopoulos E, Sfikakis PP, Pitsavos C, Tsioufis C, Panagiotakos D

This 20-year cohort study followed 3042 CVD-free adults from the ATTICA study to assess the combined impact of Lp(a) and fibrinogen on ASCVD incidence. Participants were stratified using a 30 mg/dL Lp(a) threshold and a 303 mg/dL fibrinogen median. Those with both elevated markers demonstrated the highest long-term risk (HR 1.904, 95%CI 1.023-3.547), with the association amplified only in the high Lp(a) group (HR 1.083, 95%CI 1.009-1.162; P for interaction=0.041). Path analysis indicated that fibrinogen mediates the IL-6 to ASCVD risk pathway, an effect more pronounced at higher Lp(a) concentrations. The analysis confirms synergistic risk elevation but is limited by its observational design and single European cohort.

Read the paper (DOI)PubMed

Original abstract

Aims: Elevated levels of lipoprotein(a) [Lp(a)] and fibrinogen are known risk factors for atherosclerotic cardiovascular disease (ASCVD), and their combined elevation in high-risk individuals may amplify risk. However, the long-term impact of this combination on ASCVD incidence in a primary prevention setting remains unclear. This study sought to examine the association between the combination of Lp(a) and fibrinogen with long-term ASCVD risk, in apparently healthy adults from the general population.

Methods And Results: A cohort of 3042 CVD-free adults residing in greater Athens, Greece, was recruited in 2002. A 20-year follow-up was conducted in 2022, comprising n = 2169 participants, of which n = 1988 had complete data for cardiovascular disease incidence. Participants were divided into four groups, using a recommended threshold of 30 mg/dL for Lp(a) and the median value of 303 mg/dL for fibrinogen. In the overall cohort, fibrinogen was associated with higher ASCVD risk [hazard ratio (HR) per 10 mg/dL: 1.040, 95%CI:1.009-1.072]. Upon stratification by Lp(a) levels, the significant association was retained and amplified only in individuals with elevated Lp(a) levels (HR 1.083, 95%CI:1.009-1.162) (P for interaction=0.041). Participants with both elevated Lp(a) and fibrinogen levels demonstrated the highest 20-year ASCVD risk (HR 1.904, 95%CI [1.023, 3.547]). Path analysis revealed a mediating role of fibrinogen in the inflammation [i.e. interleukin-6 (IL-6)]-ASCVD risk association, which become more pronounced at higher Lp(a) concentrations.

Conclusion: In this general population study, elevated levels of Lp(a) and fibrinogen jointly conferred a higher long-term risk of ASCVD than either marker alone, potentially through the complex involvement of inflammation.

epidemiologyinflammationriskrisk prediction

Summary written by lp-a.org from the published abstract; figures as published. Page updated 6 November 2026. Methods.